Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines - Wikidata - awgldk - TriplyDB

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

http://www.wikidata.org/entity/Q30382146

about

Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.Low acceptability of A/H1N1 pandemic vaccination in French adult population: did public health policy fuel public dissonance?Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.Estimating background rates of Guillain-Barré Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign.Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study Adverse events following pandemic A (H1N1) 2009 monovalent vaccines in pregnant women--Taiwan, November 2009-August 2010.Assessing vaccine safety communication with healthcare providers in a large urban county.Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study.Patient reported outcome data following influenza A (H1N1p) vaccination in the 2009-2010 season: web-based and telephone evaluation Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes Polymyositis following Pandemic Influenza A (H1N1) and 2009-10 Seasonal Trivalent Vaccines Pandemic Influenza A: H1N1 2009 Vaccine: A Concern on Neurological Adverse Effect.Influenza-associated neurological complications.Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study.Background rates of disease in Latin American children from a rotavirus vaccine study.Guillain-Barré syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008-2013).Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.Influenza infection and heart failure-vaccination may change heart failure prognosis?Baseline incidence of intussusception in early childhood before rotavirus vaccine introduction, the Netherlands, January 2008 to December 2012 Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes Strengthening the U.S. vaccine and immunization enterprise: the role of the National Vaccine Advisory Committee Guillain-Barré syndrome incidence in a large United States cohort (2000-2009).The expected number of background disease events during mass immunization in China.Pharmacoepidemiology.Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.Viral invasion of the amniotic cavity (VIAC) in the midtrimester of pregnancy.Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States Optimizing immunization in pediatric special risk groups.Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy.Recent developments and future directions in Guillain-Barré syndrome.Epilepsy and vaccinations: Italian guidelines.Active surveillance for adverse events following immunization.Perspectives on the future of postmarket vaccine safety surveillance and evaluation.The safety of maternal immunization.Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study.

P2860

Q22241939-6130D17D-BF31-4FB9-AE64-0F00B24F6F8A Q30369467-8559C0D9-B926-4855-A00F-F73B9F9A00B7 Q30388559-39B55CCD-1E14-4C2B-B2A0-431D1FF77099 Q30396594-096C8D01-31B5-499D-9FC4-A7EA9C9B8103 Q30402750-3C913771-9E11-4020-BE91-35D1E5752F86 Q30403078-F345E138-E1AE-46B0-8E2D-346DDDC0CE60 Q30406112-8C7FF463-F30C-46E7-BFFA-6EA3E2E5BAA7 Q30407586-814C50A1-D757-4526-B54F-C37169FF8832 Q30408530-7B5298FE-3C71-41A9-95AA-E59279F050F4 Q30409345-7BF36D16-4662-479A-B651-5DD8809130F6 Q30409462-2FE3044D-708C-42C2-BCA7-32A5BF3BD925 Q30420816-0DE2A2AA-E3C6-48BA-8ACC-F578A50E1D8A Q30423004-DA50BA70-E363-48BA-BC10-3F9E82948D0B Q30423370-C22E52BE-BD2A-47A4-80AC-9F0064DA9203 Q30428839-118D5C73-D4C8-471C-A5D0-E6765D36E255 Q30491496-DF12D6B9-89B1-42DF-A145-766881ECF67C Q31149945-213AE602-EA5E-485A-84B0-E76D546206B0 Q33403378-593B08B7-BBB1-49C1-B1A6-4280DAB5D8AD Q33708693-DAEA4A02-2DAF-44EE-A0E7-74704FADB1AA Q33851647-2A6BAFC0-14F8-490A-8B5E-BAB977B64A0D Q33916601-25711BF3-07BE-4EBE-BC7A-E9529ABCB582 Q34405697-1EB6EE01-812D-4E11-91F4-2F313128EC46 Q34640979-BB40C5F2-06D9-4D92-8262-3F034A39CC9C Q34972392-3D72E1B7-2B48-422E-9370-2183B5EF2098 Q36081506-B5C3924C-CF6B-49A7-8F71-EDCC733F2F3A Q36265065-D080EAD1-F3B0-48EB-903B-5559FC787218 Q36399720-37CF4BE0-3C82-4D43-8620-3402DAAD2DE2 Q36882923-F977ACEE-1C60-403A-9CAA-299C5ADD0A63 Q37197620-8CF8B604-433F-485A-9A4C-B340F2D2DA08 Q37320137-F9F2C056-F0D3-4D5C-9CBD-8F22C6C01C34 Q37844535-73B248CA-5413-43EB-BCE4-826405DD531B Q37908267-AF57AF2B-9454-44EC-AB71-57B9217D4287 Q38045917-A4308A59-F608-485E-B806-E7D82D94F3FC Q38070887-4F3A3E0A-5A70-470F-A7EC-5AFD3B957F74 Q38149917-618300AA-C49D-42A6-A275-E743B60D6130 Q38172268-6A5AF77D-8E2A-41A3-9A13-99F009A05638 Q38194216-EF0EAE6A-24BA-4428-83C7-9140A0CF6F65 Q38829815-53BD6D88-1717-4717-B80F-9650E6312CD9 Q38877088-83704531-79B3-4C39-84AD-4E89EB1FBFDA Q40254133-46C9E5C6-9FCE-4C10-AF3B-9F9D566DE1B6

P2860

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

http://www.wikidata.org/entity/Q30382146

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Importance of background rates ...... ndemic H1N1 influenza vaccines

@ast

Importance of background rates ...... ndemic H1N1 influenza vaccines

@en

type

label

Importance of background rates ...... ndemic H1N1 influenza vaccines

@ast

Importance of background rates ...... ndemic H1N1 influenza vaccines

@en

prefLabel

Importance of background rates ...... ndemic H1N1 influenza vaccines

@ast

Importance of background rates ...... ndemic H1N1 influenza vaccines

@en

P1433

Q30382146-5A02C599-7E18-46FE-A7AA-2B55AD1077AC

P1476

Q30382146-D1333F2D-8918-4318-8B30-935BFF796AB1

P2093

Q30382146-42A3B195-B972-4FC9-80DB-B6E24028318E

Q30382146-4F019EA4-86C4-4C2B-9ECA-B54D43985346

Q30382146-624747ED-27A3-4112-ACEE-C83ED6714F76

Q30382146-65F76DC7-7B44-4476-B46E-D2B757A1995F

Q30382146-7287CA4C-F1AF-43BD-8962-98D5E36ACEF2

Q30382146-77067BCE-5449-4F03-8C05-16454A7284E6

Q30382146-82B793FF-1A51-46D9-8483-12A0023BDB5F

Q30382146-92BDB1E2-A48A-40C0-A6FD-9B0AD0D9940A

Q30382146-9FDE8D01-A9C8-4906-8F0C-101263A454ED

Q30382146-A2BA4BBC-0C08-443B-8973-A7E3DB2F87C1

P2860

Q30382146-00765143-C352-4651-ACDD-97244B7477F7

Q30382146-0F4504A0-81DA-4115-A957-9B4D4D8E18CD

Q30382146-16464C14-FAA6-48BD-8855-6933110BAA26

Q30382146-1A9F7996-1CD3-425A-AF10-02F83B027780

Q30382146-35EEEE46-1143-43B3-A020-3FF73998843A

Q30382146-3623EEB6-E73A-4A7A-B139-6D352A7DE6B0

Q30382146-3DC2E87F-3F09-4D6B-BF30-F083C4984E38

Q30382146-3EA31253-E769-40ED-9474-1D245930FD11

Q30382146-41899AD7-3399-4EB2-8A9C-ABB2390418D6

Q30382146-550FEDF9-61B1-4B3F-8C6A-D196864D2162

P304

Q30382146-78D7E968-ECB6-4392-8DB4-8412F6860087

P31

Q30382146-70914446-4D65-4CF2-9BD2-97DA6E2A800D

P356

Q30382146-233FAC2E-BDF4-49BF-9C24-A711287BA17A

P407

Q30382146-D5C2290E-B9A1-483C-9C4F-3F1175D530B7

P433

Q30382146-5AF3E92A-2E3C-4226-8F91-4F08D8127C21

P478

Q30382146-D9C5C5B4-D752-4F56-9602-896616B1F808

P50

Q30382146-1933A78F-250A-41B1-B698-3F199AB14A32

Q30382146-49063CD0-8B08-4FCB-B5A6-3EBE207703F6

P577

Q30382146-1445E696-E910-4C9C-8C58-DD551A2E276C

P698

Q30382146-54CD44FE-A5F9-456C-9D35-F89445A398E3

P921

Q30382146-02FC4C7E-8280-4394-B0ED-7ADF65D2BB5D

P932

Q30382146-C97B6586-59E3-4EF5-B9D8-ED5D85B0625A

P356

S0140-6736(09)61877-8

P1433

P1476

Importance of background rates ...... ndemic H1N1 influenza vaccines

@en

P2093

Aysha Akhtar

http://www.w3.org/2001/XMLSchema#string

Barbara Law

http://www.w3.org/2001/XMLSchema#string

Claudia Vellozzi

http://www.w3.org/2001/XMLSchema#string

Dina Pfeifer

http://www.w3.org/2001/XMLSchema#string

Elizabeth Miller

http://www.w3.org/2001/XMLSchema#string

Gabriel Oselka

http://www.w3.org/2001/XMLSchema#string

Hector S Izurieta

http://www.w3.org/2001/XMLSchema#string

Juhani Eskola

http://www.w3.org/2001/XMLSchema#string

Julia Stowe

http://www.w3.org/2001/XMLSchema#string

Kirsten Vannice

http://www.w3.org/2001/XMLSchema#string

P2860

Optic neuritis: A population-based study in Olrnsted County, Minnesota

Risk of anaphylaxis after vaccination of children and adolescents

Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease.

Reference population for international comparisons and time trend surveillance of preterm delivery proportions in three countries.

Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database.

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.

Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.

Sudden death in young adults: a 25-year review of autopsies in military recruits.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

The science of evaluation of adverse events associated with vaccination.

P304

2115-2122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(09)61877-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

9707

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Daniel A Salmon

Claire-Anne Siegrist

P577

2009-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19880172

http://www.w3.org/2001/XMLSchema#string

P921

P932

2861912

http://www.w3.org/2001/XMLSchema#string